Table 3. Clinical characteristics and ratings among participants with MCI due to AD based on APOΕ4 carrier status.
Clinical characteristics are shown for individual studies, but pooled for calculating statistical significance of between-group differences.
| Study Name | ADNI | MIS trial | Overall | |||||
|---|---|---|---|---|---|---|---|---|
| ε4− | ε4+ | ε4− | ε4+ | ε4− | ε4+ | P-value | ||
| N | (N=187) | (N=215) | (N=357) | (N=433) | (N=544) | (N=648) | ||
| Age, years | 1134 | 75.7 (8.1) | 73.8 (6.7) | 72.2 (8.0) | 72.4 (6.5) | 73.4 (8.2) | 72.9 (6.6) | 0.054 |
| Education, years | 1134 | 15.7 (3.1) | 15.7 (3.0) | 14.6 (3.2) | 14.7 (3.0) | 15.0 (3.2) | 15.0 (3.1) | 0.73 |
| Ethnicity, Hispanic | 1134 | 8 (4%) | 6 (3%) | 19 (6%) | 9 (2%) | 27 (5%) | 15 (2%) | 0.013 |
| Marital status, married | 1182 | 143 (78%) | 172 (80%) | 251 (71%) | 353 (82%) | 394 (73%) | 525 (82%) | <0.001 |
| Race, White | 1134 | 165 (93%) | 196 (94%) | 303 (90%) | 384 (94%) | 468 (91%) | 580 (94%) | 0.046 |
| Gender, Female | 1134 | 60 (34%) | 77 (37%) | 146 (43%) | 194 (47%) | 206 (40%) | 271 (44%) | 0.18 |
| APOE ε2 Carrier | 1192 | 17 (9%) | 11 (5%) | 52 (15%) | 21 (5%) | 69 (13%) | 32 (5%) | <0.001 |
| Baseline CDRsb | 402 | 1.52 (0.85) | 1.68 (0.89) | 1.70 (0.77) | 1.90 (0.78) | 1.52 (0.85) | 1.68 (0.89) | 0.049 |
| Baseline MMSE | 1192 | 27.1 (1.8) | 26.9 (1.8) | 27.5 (1.9) | 27.1 (1.8) | 27.3 (1.8) | 27.1 (1.8) | 0.005 |
| ADAS-Cog Scores | ||||||||
| Baseline | 402 | 10.5 (4.4) | 12.4 (4.3) | 10.4 (4.1) | 12.0 (4.5) | 10.4 (4.2) | 12.1 (4.4) | <0.001 |
| 6 months | 1038 | 11.5 (5.5) | 13.0 (5.4) | 9.3 (4.8) | 11.8 (5.1) | 10.2 (5.2) | 12.2 (5.2) | <0.001 |
| 12 months | 972 | 11.6 (6.2) | 13.5 (6.1) | 9.9 (5.1) | 12.8 (5.8) | 10.6 (5.6) | 13.0 (5.9) | <0.001 |
| 18 months | 872 | 12.1 (6.7) | 14.8 (7.7) | 10.0 (5.1) | 13.6 (6.6) | 10.8 (5.8) | 14.0 (7.0) | <0.001 |
| 24 months | 814 | 12.6 (7.4) | 15.3 (7.3) | 9.6 (5.6) | 14.4 (7.3) | 10.7 (6.5) | 14.7 (7.3) | <0.001 |